Connect with us

Technology

Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator (DxA) invests $10M in Alamar Biosciences, Inc. to Advance Precision Medicine in Alzheimer’s Disease

Published

1 year ago

on

Largest DxA investment to date supports development of Alamar’s ARGO™ DX System and future in vitro diagnostic tests

NEW YORK and FREMONT, Calif., Jan. 8, 2025 /PRNewswire/ — The Alzheimer’s Drug Discovery Foundation (ADDF)‘s Diagnostics Accelerator (DxA) today announced a $10M investment in Alamar Biosciences, Inc. This landmark investment, the largest in DxA history, will expedite the translation of the ARGO-HT research platform into an FDA-cleared system to support the development of in vitro diagnostic (IVD) tests – the gold standard of diagnostics. Alamar’s ARGO HT System automates high-throughput NULISA™ assays, offering ultrasensitive protein detection and multiplexing for analyzing blood-based biomarkers related to Alzheimer’s and other dementias.

“In cancer and other diseases of aging, we have biomarker panels that allow clinicians to better differentiate from many underlying causes of the disease and more importantly, how to tailor treatments based on each patient’s individual biomarker profile,” said Howard Fillit, MD, Co-Founder and Chief Science Officer at the ADDF. “There is a pressing need to have biomarker panels for Alzheimer’s patients so we can better diagnose and develop new treatments. Alamar’s innovative platform provides the opportunity for a first of its kind blood panel in Alzheimer’s, which will be an important step as we move forward to delivering a more personalized approach for patients.”

“The powerful combination of ultra-high sensitivity and multiplexing unlocks the potential to measure novel biomarker signatures, enabling differential diagnosis in neurodegeneration,” said Niranjan Bose, Managing Director, Health and Life Sciences at Gates Ventures. “The investment in the development of ARGO DX focuses on translating this capability onto a scalable platform for widespread clinical use. We are excited to partner with the Alamar team to bring this vision to reality and advance the molecular diagnostics landscape in Alzheimer’s disease.”

The holy grail for Alzheimer’s diagnostics is to develop an accessible and scalable blood panel that can detect multiple biomarkers, providing clinicians with a better understanding of each patient’s individual disease biology. Alamar’s NULISA™ technology is unique in that it enables ultra-high sensitivity with the ability to test for multiple targets at once.

“Experts in the field have showcased the performance of the NULISA technology in detecting essentially all the important biomarkers in blood for Alzheimer’s and related dementias,” said Yuling Luo, Ph.D., Founder, Chairman, and CEO of Alamar Biosciences, Inc. “The ARGO DX platform can potentially revolutionize the biomarker space by allowing researchers to go from discovery to detection of biomarker panels that stratify patient subsets and disease factors that would otherwise have gone unnoticed.”

“A diagnostic platform such as Alamar’s, that can detect and measure multiple disease pathways, will be instrumental in paving the way for early detection, biology of aging-based differential diagnosis, allowing for a precision medicine approach in Alzheimer’s,” commented Dr. Fillit.

This recent investment in Alamar reflects the DxA’s larger vision to accelerate the development of new biomarkers and diagnostic tools to enable early detection and diagnosis of Alzheimer’s. To date, the DxA has invested more than $80 million in nearly 70 projects, underscoring its commitment to bringing accessible, affordable, and scalable diagnostics to patients struggling with Alzheimer’s disease. Along with blood tests, the DxA’s diverse portfolio includes retinal scans and digital tools that will not only provide patients with early and accurate diagnoses but also work in tandem and have the potential to be used for screening, prognostic, and prevention efforts. 

About The Alzheimer’s Drug Discovery Foundation (ADDF)
Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer’s Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer’s disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer’s, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF’s leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer’s PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $360 million to fund over 760 Alzheimer’s drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: http://www.alzdiscovery.org/.

ABOUT THE DIAGNOSTICS ACCELERATOR (DxA)
The Diagnostics Accelerator, created in July 2018, is a $100 million global research initiative from partners including ADDF Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, the Charles and Helen Schwab Foundation, The Association for Frontotemporal Degeneration, among others, to develop novel biomarkers for the early detection of Alzheimer’s disease and related dementias.

This research initiative is dedicated to accelerating the development of affordable and accessible biomarkers to diagnose Alzheimer’s disease and related dementias and advance the clinical development of more targeted treatments. Through translational research awards and access to consulting support from industry experts, this program will challenge, assist and fund the research community in both academia and industry to develop novel peripheral and digital biomarkers.

About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company’s proprietary NULISA Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/alzheimers-drug-discovery-foundations-diagnostics-accelerator-dxa-invests-10m-in-alamar-biosciences-inc-to-advance-precision-medicine-in-alzheimers-disease-302345929.html

SOURCE Alzheimer’s Drug Discovery Foundation

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Florida Physician Specialists Data Breach: Edelson Lechtzin LLP Launches Investigation into Exposure of Personal Information

Published

1 hour ago

on

May 3, 2026

By

National class action firm offering free case evaluations to individuals impacted by the Florida Physician Specialists cybersecurity incident

JACKSONVILLE, Fla., May 3, 2026 /PRNewswire/ — Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from the Florida Physician Specialists data breach. Florida Physician Specialists learned of the cybersecurity incident between November 27 and 29, 2025.

What Happened

Florida Physician Specialists discovered that its network was hacked between November 27 and 29, 2025. An investigation launched in late November 2025 confirmed that an unauthorized third party accessed its network. The review of the exposed data was completed on April 6, 2026.

Information Exposed

Affected personal data includes full names and one or more of the following: Social Security numbers, driver’s license numbers or state identification numbers, other government identification numbers, financial account information, credit or debit card information, medical information, and/or health insurance policy information.

Who May Be Impacted

Individuals who received a data breach notification from Florida Physician Specialists may face an increased risk of identity theft and fraud.

Your Legal Options

Edelson Lechtzin LLP is investigating a potential class action to pursue legal remedies on behalf of individuals whose sensitive personal data may have been compromised in the Florida Physician Specialists breach. The firm will evaluate your rights and potential claims at no cost.

Recommended Protective Steps

Review account statements and credit reports regularly and remain vigilant for suspicious activity. Confirm whether your information was involved in the Florida Physician Specialists incident and preserve any letters or emails you received about the breach. Consider placing fraud alerts and credit monitoring.

Contact Us for a Free Case Evaluation

Speak confidentially with a data privacy attorney today: Marc Edelson, Esq., Edelson Lechtzin LLP, 411 S. State Street, Suite N-300, Newtown, PA 18940; Phone: 844-696-7492 ext. 2; Email: medelson@edelson-law.com; Web: www.edelson-law.com. Or click HERE to request a free consultation.

About Florida Physician Specialists

Based in Jacksonville, Florida, Florida Physician Specialists is a multi-specialty private physician practice serving patients in Northeast Florida.

About Edelson Lechtzin LLP

Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to data breach litigation, the firm handles class and collective actions involving securities and investment fraud, federal antitrust violations, ERISA employee benefit plans, wage theft, and consumer fraud

Media and Partnership Inquiries: Use the contact information above to connect with our team regarding interviews, co-counsel opportunities, and referral partnerships.

Legal Notice: This press release may be considered Attorney Advertising in some jurisdictions.

View original content to download multimedia:https://www.prnewswire.com/news-releases/florida-physician-specialists-data-breach-edelson-lechtzin-llp-launches-investigation-into-exposure-of-personal-information-302760742.html

SOURCE Edelson Lechtzin LLP

Continue Reading

Technology

Sandhills Medical Foundation, Inc., d/b/a Sandhills Medical Data Breach: Edelson Lechtzin LLP Launches Investigation into Exposure of Personal Information

Published

1 hour ago

on

May 3, 2026

By

National class action firm offering free case evaluations to individuals impacted by the Sandhills Medical cybersecurity incident

MCBEE, S.C., May 3, 2026 /PRNewswire/ — Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from the Sandhills Medical data breach. Sandhills Medical learned of the cybersecurity incident between November 27 and 29, 2025.

What Happened

On May 8, 2025, Sandhills Medical discovered it had been the victim of a ransomware attack. Sandhills Medical began an investigation with the help of cybersecurity experts and a forensic firm. That investigation determined an unauthorized third party accessed Sandhills Medical’s server directly and obtained personal information for select patients.

Information Exposed

Affected personal data includes names, personal health information, and birth dates. This data breach has affected an estimated 169,017 people.

Who May Be Impacted

Individuals who received a data breach notification from Sandhills Medical may face an increased risk of identity theft and fraud.

Your Legal Options

Edelson Lechtzin LLP is investigating a potential class action to pursue legal remedies on behalf of individuals whose sensitive personal data may have been compromised in the Sandhills Medical breach. The firm will evaluate your rights and potential claims at no cost.

Recommended Protective Steps

Review account statements and credit reports regularly and remain vigilant for suspicious activity. Confirm whether your information was involved in the Sandhills Medical incident and preserve any letters or emails you received about the breach. Consider placing fraud alerts and credit monitoring.

Contact Us for a Free Case Evaluation

Speak confidentially with a data privacy attorney today: Marc Edelson, Esq., Edelson Lechtzin LLP, 411 S. State Street, Suite N-300, Newtown, PA 18940; Phone: 844-696-7492 ext. 2; Email: medelson@edelson-law.com; Web: www.edelson-law.com. Or click HERE to request a free consultation.

About Sandhills Medical

Based in McBee, South Carolina, Sandhills Medical operates as a Federally Qualified Community Health Center (FQHC) that provides community-based primary health care services.

About Edelson Lechtzin LLP

Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to data breach litigation, the firm handles class and collective actions involving securities and investment fraud, federal antitrust violations, ERISA employee benefit plans, wage theft, and consumer fraud

Media and Partnership Inquiries: Use the contact information above to connect with our team regarding interviews, co-counsel opportunities, and referral partnerships.

Legal Notice: This press release may be considered Attorney Advertising in some jurisdictions.

View original content to download multimedia:https://www.prnewswire.com/news-releases/sandhills-medical-foundation-inc-dba-sandhills-medical-data-breach-edelson-lechtzin-llp-launches-investigation-into-exposure-of-personal-information-302760743.html

SOURCE Edelson Lechtzin LLP

Continue Reading

Technology

Danish Publisher Automates Digital Textbook Delivery with Integrated WooCommerce-Webdoxx Solution

Published

6 hours ago

on

May 3, 2026

By

Danish educational publisher eliminates manual processing errors and delivers instant access to more than 20 digital learning products

LONDON, May 3, 2026 /PRNewswire-PRWeb/ — Forlaget 94, a Danish educational publisher serving commercial colleges and vocational schools since 1994, has transformed its digital textbook distribution by implementing a fully automated WooCommerce-Webdoxx solution.

“Using the Webdoxx-WooCommerce integration we have achieved full automation of order processing, fewer errors, and happier customers,” Tom Gertsen, IT Manager at Forlaget 94

Previously, Forlaget 94 relied on manual processes to distribute digital textbooks to customers. As demand for online educational materials grew, the publisher required a faster, more reliable way to manage orders, provision access, and reduce the risk of administrative errors.

Through its integration of WooCommerce with Webdoxx, Forlaget 94 now runs more than 20 educational products through a 100% automated workflow. The solution automatically processes customer orders and provides instant access to purchased digital textbooks, improving the experience for both customers and internal teams.

“The result is full automation of order processing, fewer errors, and happier customers,” said Tom Gertsen, IT Manager at Forlaget 94 and architect behind the WooCommerce-Webdoxx integration. The automated system has enabled Forlaget 94 to eliminate manual errors, accelerate customer processing, and increase customer satisfaction through immediate access provisioning. The implementation demonstrates how educational publishers can modernize digital content delivery while maintaining secure, managed access to learning materials.

Webdoxx, a service created and managed by Drumlin Security Ltd, provides online DRM and managed document delivery services for publishers, educational organizations, institutions, and commercial content providers.

About Forlaget 94

Forlaget 94 is a Danish educational publisher established in 1994, providing educational products for commercial colleges and vocational schools.

About Webdoxx

Webdoxx is an online DRM and managed document delivery service created and managed by Drumlin Security Ltd. The platform supports secure access to digital publications and documents across a range of sectors, including education, healthcare, government, finance, and publishing.

Media Contact

Mike de Smith, Drumlin Security Ltd, 44 7768404712, info@drumlinsecurity.com, https://www.drumlinsecurity.com/

View original content to download multimedia:https://www.prweb.com/releases/danish-publisher-automates-digital-textbook-delivery-with-integrated-woocommerce-webdoxx-solution-302759942.html

SOURCE Forlaget 94

Continue Reading

Trending